Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C virus genotype 1 (HCV-1) infection. We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR.


Published in:
Gastroenterology, 139, 1, 120-9
Year:
2010
ISSN:
1528-0012
Keywords:
Laboratories:




 Record created 2011-04-11, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)